There are 3161 resources available
Discussion led by Chair
Presenter: Manuel Irimia
Session: Pharmacologically manipulating evolution
Resources:
Webcast
Should we try immunotherapy for all patients with advanced cancer? - No
Presenter: Kok Haw Jonathan Lim
Session: YO Boxing session
Resources:
Slides
Webcast
Discussion led by Chair
Presenter: Helen Gogas
Session: How to optimally counsel my melanoma patients for adjuvant therapy
Resources:
Slides
Webcast
1436P - Better overall survival of male versus female patients with advanced gastric adenocarcinoma
Presenter: Minggui Pan
Session: Poster session 18
375P - Results from the Danish Breast Cancer Group's (DBCG) NAME-trial: A direct comparison of oral navelbine given either classic or metronomic in metastatic breast cancer
Presenter: Anne Sofie Brems-Eskildsen
Session: Poster session 15
Discussion
Session: YO Boxing session
Resources:
Webcast
1437P - Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up
Presenter: Marcia Cruz-Correa
Session: Poster session 18
1438P - First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW
Presenter: Yoon-Koo Kang
Session: Poster session 18
376P - Evaluating adherence to oral anticancer medications in metastatic and non-metastatic breast cancer patients
Presenter: Rana El-Shewy
Session: Poster session 15